Evidence map›Paper›PMID 37867521›Full record

ArticleFrontiers in endocrinology2023

Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.

Hong-Yu Zhang, Han-Yong Yu, Guo-Xu Zhao, Xin-Zhan Jiang, Ge Gao, Bao-Jian Wei

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hong-Yu ZhangDepartment of Neurosurgery, Harbin Medical University, Harbin, China.
Han-Yong YuDepartment of Neurosurgery, Harbin Medical University, Harbin, China.
Guo-Xu ZhaoDepartment of Medical Imaging, Mudanjiang Medical University, Mudanjiang, China.
Xin-Zhan JiangDepartment of Neurosurgery, Harbin Medical University, Harbin, China.
Ge GaoDepartment of Gastrointestinal Surgery, Linyi People's Hospital, Linyi, China.
Bao-Jian WeiSchool of Nursing, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, Shandong, China.
Harbin Medical University · CNLinyi People's Hospital · CNMudanjiang Medical University · CNShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioma is a prevalent and lethal brain malignancy; despite current treatment options, the prognosis remains poor. Therefore, immunotherapy has emerged as a promising therapeutic strategy. However, research trends and hotspots in glioma immunotherapy have not been systematically analyzed. This study aimed to elucidate global research trends and knowledge structures regarding immunotherapy for glioma using bibliometric analysis. Methods: Publications related to immunotherapy for glioma from 2000-2023 were retrieved from Web of Science Core Collection database (WoSCC). We conducted quantitative analysis and visualization of research trends using various tools, including VOSviewer (1.6.18), CiteSpace (5.7 R3), Microsoft Charticulator, and the Bibliometrix package in R. Results: A total of 4910 publications were included. The number of annual publications exhibited an obvious upward trend since 2019. The USA was the dominant country in terms of publication output and centrality. Conclusion: This bibliometric analysis systematically delineated global landscapes and emerging trends in glioma immunotherapy research. This study highlighted the prominence of Chimeric Antigen Receptor T-cell (CAR-T), Programmed Death-1 (PD-1), and nivolumab in current glioma immunotherapy research. The growing emphasis on specific neoantigens and prognostic tumor markers suggests potential avenues for future exploration. Furthermore, the data underscores the importance of strengthened international collaboration in advancing the field.

Indexed as

GliomaReceptors, Chimeric AntigenBibliometricsHumansImmunotherapyNivolumabTumor MicroenvironmentNivolumabReceptors, Chimeric AntigenbibliometricCAR-TCitespacegliomaimmunotherapyVOSviewer

Identifiers

PMID37867521
PMCPMC10585102
OpenAlexW4387374972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.